SCHEDULE: Nantahala Capital Management Discloses Senti Biosciences Stake

Nantahala Capital Management, LLC, along with principals Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 4.10% of Senti Biosciences Holdings, Inc. common stock as of September 30, 2026.

Summary

• Nantahala Capital Management, LLC, and its managing members Wilmot B. Harkey and Daniel Mack, have filed a Schedule 13G, indicating their beneficial ownership of Senti Biosciences Holdings, Inc. common stock.
• As of September 30, 2026, the Reporting Persons collectively beneficially own 1,332,000 shares, representing 4.10% of the class of securities.
• This ownership includes shares that may be acquired within sixty days through the exercise of convertible securities.
• Nantahala Capital Management, LLC is identified as an investment adviser, and Messrs. Harkey and Mack are filing as control persons of Nantahala.
• The filing asserts that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant but not overwhelming stake by Nantahala Capital Management, LLC and its principals in Senti Biosciences Holdings, Inc. The filing itself is a standard disclosure and doesn't contain operational or financial performance data, thus limiting a more definitive sentiment.

Positives

• Nantahala Capital Management, LLC, a recognized investment manager, has taken a notable stake in Senti Biosciences Holdings, Inc., suggesting confidence in the company's potential.
• The disclosure of a 4.10% stake indicates a significant level of investment by sophisticated market participants.

Negatives

• The filing is a Schedule 13G, which is a passive ownership filing and does not provide details on the company's operational performance or financial health.
• The filing does not offer any forward-looking statements or specific strategic insights into Senti Biosciences Holdings, Inc.

Risks

• The filing does not explicitly mention any risks associated with the investment or the company itself.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. Nantahala Capital Management's filing indicates a substantial investment in Senti Biosciences Holdings, Inc., a company operating in the biotechnology sector, which is characterized by innovation and significant growth potential but also inherent risks.

Stakeholder Impact

• Shareholders: The filing may signal increased institutional interest in Senti Biosciences Holdings, Inc., potentially influencing market perception and share price.
• Management: The disclosure of a significant stake by Nantahala Capital Management may lead to increased scrutiny or engagement from the reporting persons.

Next Steps

• Continue to monitor future filings from Nantahala Capital Management and Senti Biosciences Holdings, Inc. for further insights into ownership and company performance.

Key Dates

Keywords

Senti Biosciences Holdings, Nantahala Capital Management, Schedule 13G, Beneficial Ownership, Investment Adviser, Common Stock, Wilmot B. Harkey, Daniel Mack